New therapeutic target for pediatric anaplastic ependymoma control: study of anti-tumor activity by a Kunitz-type molecule, Amblyomin-X
Universidade Federal de São Paulo (UNIFESP)¦¦Brasil ; Universidade Humboldt de Berlim¦¦Alemanha ; German Cancer Research Center¦¦Alemanha ; Charité Universitätsmedizin¦¦Alemanha ; Hospital Israelita Albert Einstein¦¦Brasil ; Universidade de São Paulo (USP)¦¦Brasil ; Universidade de Brasília (UNB)¦¦Brasil
Appears in Collections:
EPNs comprise a heterogeneous group of neuroepithelial tumors, accounting for about 10% of all intracranial tumors in children and up to 30% of brain tumors in those younger than 3 years. Actually, the pattern therapy for low-grade EPNs includes complete surgical resection followed by radiation therapy. Total surgical excision is often not possible due to tumor location. The aim of this study was to evaluate, for the first time, the anti-tumor activity of Amblyomin-X in 4 primary cultures derived from pediatric anaplastic posterior fossa EPN, Group A (anaplastic, WHO grade III) and one primary culture of a high grade neuroepithelial tumor with MN1 alteration, which was initially misdiagnosed as EPN: i) by in vitro assays: comparisons of temozolomide and cisplatin; ii) by intracranial xenograft model. Amblyomin-X was able to induce cell death in EPN cells in a more significant percentage compared to cisplatin. The cytotoxic effects of Amblyomin-X were not detected on hFSCs used as control, as opposed to cisplatin-treatment, which promoted a substantial effect in the hAFSCs viability. TEM analysis showed ultrastructural alterations related to the process of cell death: mitochondrial degeneration, autophagosomes and aggregate-like structures. MRI and histopathological analyzes demonstrated significant tumor mass regression. Our results suggest that Amblyomin-X has a selective effect on tumor cells by inducing apoptotic cell death and may be a therapeutic option for Group AEPNs.
Pavon LF, Capper D, Sibov TT, Toledo SRC, Thomal U-W, Souza JG, et al. New therapeutic target for pediatric anaplastic ependymoma control: study of anti-tumor activity by a Kunitz-type molecule, Amblyomin-X. Sci. Rep.. 2019 Jul;9:9973. doi:10.1038/s41598-019-45799-4.
Link to cite this reference
The access to the publications deposited in this repository respects the licenses from journals and publishers.